Molecules for Nociceptor Force Transduction
This project aims to identify and target specific molecules involved in nociceptor force transduction to develop new pain therapies.
Projectdetails
Introduction
Pain results from activation of the nociceptive sensory system, which is built upon the primary afferent nociceptor, a type of sensory neuron specialized to detect, code, and relay information about potentially or actually damaging stimuli. Humans lacking properly functioning nociceptors never experience pain and have reduced life expectancy, suffering severe disability.
Nociceptor Function
Nociceptors detect sustained force into ranges that are potentially damaging, and sustained nociceptor activation will always lead to pain. It has been assumed that mechanical force transduced by nociceptors requires mechanically activated ion channels in the nociceptor membrane.
Recent Findings
However, recent data suggests that sensory Schwann cells that wrap the nociceptor ending also participate in force transduction. The aim of this proposal is to identify molecules specifically involved in nociceptor force transduction at this neuroglial site.
Identified Molecules
We have already identified:
- An ion channel (Tmem87a/ELKIN1)
- An extracellular tether protein (TENM4)
These molecules are involved in nociceptor force transduction. In addition, STOML3 modulates ELKIN1 function and can sensitize almost all nociceptors to mechanical force.
Research Approach
The identification of a set of molecules involved in force transduction (ELKIN1/TENM4/STOML3) will allow us to design “guilt by association” approaches to identify new players. We will use:
- Ultra-low input spatial proteomics
- BioID
- High throughput electrophysiological screening
to achieve this aim.
Genetic Strategies
We have designed novel genetic strategies to interrogate the function of candidate proteins in nociceptor force transduction, with timescales ranging from weeks to minutes.
Project Impact
This ambitious and challenging project promises to deliver novel molecular targets that can be used to specifically target nociceptor force transduction. Specific targeting of nociceptor force transduction could be a powerful new way to treat multiple pain types poorly served by existing therapies.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.500.000 |
Totale projectbegroting | € 2.500.000 |
Tijdlijn
Startdatum | 1-7-2024 |
Einddatum | 30-6-2029 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC)penvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Uncovering the cortical cellular basis of specificity and chronicity of painThis project aims to identify and manipulate neocortical neuronal ensembles to understand their role in pain perception and develop non-invasive methods for chronic pain relief. | ERC Advanced... | € 2.468.700 | 2025 | Details |
Descending control of painDescendPain aims to classify RVM neuron types and uncover how brain modulation of pain varies with affective states, potentially transforming pain treatment strategies. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Engineering synthetic mechanotransduction through nucleocytoplasmic transportThis project aims to engineer synthetic mechanotransduction in cells to control gene expression through mechanical signals, enhancing our understanding of cell behavior in response to tissue mechanics. | ERC Advanced... | € 2.499.875 | 2023 | Details |
PERSONALIZED NON-INVASIVE NEUROMODULATION IN PAINPersoNINpain aims to personalize chronic pain treatment by using brain connectivity metrics to optimize non-invasive neuromodulation techniques like rTMS for individual patients. | ERC Consolid... | € 1.618.278 | 2023 | Details |
Chronic PAIN eradiCAtion by taRgeting Schwann cEllsPAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization. | ERC Proof of... | € 150.000 | 2023 | Details |
Uncovering the cortical cellular basis of specificity and chronicity of pain
This project aims to identify and manipulate neocortical neuronal ensembles to understand their role in pain perception and develop non-invasive methods for chronic pain relief.
Descending control of pain
DescendPain aims to classify RVM neuron types and uncover how brain modulation of pain varies with affective states, potentially transforming pain treatment strategies.
Engineering synthetic mechanotransduction through nucleocytoplasmic transport
This project aims to engineer synthetic mechanotransduction in cells to control gene expression through mechanical signals, enhancing our understanding of cell behavior in response to tissue mechanics.
PERSONALIZED NON-INVASIVE NEUROMODULATION IN PAIN
PersoNINpain aims to personalize chronic pain treatment by using brain connectivity metrics to optimize non-invasive neuromodulation techniques like rTMS for individual patients.
Chronic PAIN eradiCAtion by taRgeting Schwann cElls
PAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
HB-086 and HB-097 for Treatment of Chronic Sensory Neuronal Disorders - Neuropathic Pain and Hearing LossHB-086 and HB-097 are therapeutic proteins targeting sensory nerve cells to treat chronic pain and hearing loss, demonstrating significant pain relief and hearing preservation in preclinical models. | EIC Accelerator | € 2.325.312 | 2022 | Details |
PN6047 - a breakthrough treatment of neuropathic painPharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development. | EIC Accelerator | € 2.493.000 | 2024 | Details |
HB-086 and HB-097 for Treatment of Chronic Sensory Neuronal Disorders - Neuropathic Pain and Hearing Loss
HB-086 and HB-097 are therapeutic proteins targeting sensory nerve cells to treat chronic pain and hearing loss, demonstrating significant pain relief and hearing preservation in preclinical models.
PN6047 - a breakthrough treatment of neuropathic pain
PharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development.